NEW YORK – Chinese precision oncology platform company Genetron Holdings and its strategic partner CStone Pharmaceuticals said on Friday that they have launched a multi-center clinical trial in China for the joint development of a companion diagnostic test for avapritinib (Blueprint Medicines's Ayvakit).